BlackRock, Inc. 13D and 13G filings for BioXcel Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-09 09:02 am Sale |
2023-01-31 | 13G | BioXcel Therapeutics, Inc. BTAI |
BlackRock Inc. BLK |
82,025 4.700% |
-9,407 (-10.29%) |
Filing |
| 2023-02-03 12:10 pm Purchase |
2022-12-31 | 13G | BioXcel Therapeutics, Inc. BTAI |
BlackRock Inc. BLK |
91,433 5.200% |
91,433 (New Position) |
Filing |